Medidata Solutions will be showcasing new products, presenting in educational sessions and demonstrating key integrations at this week’s 47th Annual Meeting of the Drug Information Association (DIA) in Chicago, Ill.
“Through our executive presentations, booth demonstrations and participation in the Interoperability Showcase, we look forward to showcasing Medidata's approach to helping clinical researchers optimize their clinical trials at the DIA Annual Meeting," said Tarek Sherif, chairman and CEO of Medidata Solutions. "We will be introducing new products and capabilities and demonstrating our full product platform as we participate in the industry's premier networking and education event."
New Products Address Sponsor Pain Points Across Clinical Development Chain
From booth #1101, Medidata will be providing demos of key products, including:
Medidata Rave Integrates with EMRs at Interoperability Showcase
Medidata is also sponsoring DIA’s inaugural Interoperability Showcase. The Showcase, led by DIA, CDISC, HIMSS and the IHE, will offer demonstrations of new solutions that facilitate improved clinical research and safety reporting capabilities.
In the Showcase, Medidata will demonstrate integrations with electronic medical records (EMRs) and other systems, highlighting how standards-based IT solutions can improve data information exchange between systems, providers and organizations to optimize clinical care and research.
Executive Speakers Drive Discussion on Key Topics and Trends in Research and Development
Medidata executives will be leading the following sessions this week:
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.